Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (113)	7/2/1998 10:08:00 PM
From: mike head	Respond to of 626

TD. After a few minutes reading on a coupla Yahoo! threads, I return here for a breath of civility! Quiet here, though; are we eclipsed by Geneva? (Lived in CH for awhile, and 80% of those folk called it Genf, or Gaenf- not Geneva!). Anything new with TTNP?- gotta be something. Pax et Bonum, mch

To: Miljenko Zuanic who wrote (113)	7/11/1998 2:36:00 PM
From: Timothy Kross	Read Replies (2) \| Respond to of 626

To: All From: Tim I just received the 1997 annual report from Titan Pharmaceutical in the mail. One little tidbit seemed very interesting to me. Novartis has worldwide rights to iloperidone but Titan kept the rights to Japan for themselves. If iloperidone makes it, then that should be quite a market. Japan has 125,000,000 people. Let's assume that 1% have schizophrenia. That makes a market of 1.25 million people with schizophrenia in Japan. Let's say that iloperidone grabs a 20% share of the market. That's 250,000 people in Japan that could be on iloperidone. Let's say they make $500 per year per patient. If these estimates ever do come true, then that's $ 125 million per year profits to Titan Pharmaceuticals just on the schizophrenia market in Japan. Any of these assumptions could be off. I have tried to make my estimates on the conservative side. One thing is sure, the Japanese are a rich nation. Its people sure would be able to afford the new generation serotonin dopamine antipsychotics, and they would probably prefer these newer agents to the older generation phenothiazines which have a much higher side effect profile.

To: Miljenko Zuanic who wrote (113)	7/12/1998 1:25:00 AM
From: Lel H	Read Replies (1) \| Respond to of 626

OT to Miljenko Zuanic: I just wanted to send a special hello to you here. We got to know each other on the IPIC board on Yahoo!, where I post under the handle "lelim". We had our differences, but fundamentally I enjoyed our conversations. It's nice to see you around again. The TTNP board at Yahoo! could benefit from your input, though the board has been infested by, well, a bunch of yahoos who don't have anything useful to say. Best wishes, Lel